4.6 Article

Kinetics of Neutralizing Antibodies of COVID-19 Patients Tested Using Clinical D614G, B.1.1.7, and B 1.351 Isolates in Microneutralization Assays

期刊

VIRUSES-BASEL
卷 13, 期 6, 页码 -

出版社

MDPI
DOI: 10.3390/v13060996

关键词

SARS-CoV-2; neutralizing antibodies; immunity

类别

资金

  1. Jane and Aatos Erkko Foundation
  2. EU Horizon [874735]
  3. Academy of Finland
  4. Helsinki University Hospital Funds [TYH2018322]

向作者/读者索取更多资源

Newly emerged SARS-CoV-2 variants of concern show resistance to neutralization by antibodies elicited by the wild-type virus, with VoC2 having increased potential to reinfect previously SARS-CoV-infected individuals. Neutralizing antibodies in recovered patients show varied levels of inhibition against different variants, with some sera failing to neutralize VoC2.
Increasing evidence suggests that some newly emerged SARS-CoV-2 variants of concern (VoCs) resist neutralization by antibodies elicited by the early-pandemic wild-type virus. We applied neutralization tests to paired recoveree sera (n = 38) using clinical isolates representing the first wave (D614G), VoC1, and VoC2 lineages (B.1.1.7 and B 1.351). Neutralizing antibodies inhibited contemporary and VoC1 lineages, whereas inhibition of VoC2 was reduced 8-fold, with 50% of sera failing to show neutralization. These results provide evidence for the increased potential of VoC2 to reinfect previously SARS-CoV-infected individuals. The kinetics of NAbs in different patients showed similar decline against all variants, with generally low initial anti-B.1.351 responses becoming undetectable, but with anti-B.1.1.7 NAbs remaining detectable (>20) for months after acute infection.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据